The merger creates a new diagnostics-focused entity with a small float and concentrated ownership via the Stockholders Agreement. Monitor the first combined quarterly report for revenue and cash runway from DiamiR's CLIA lab operations. The Series A Preferred Stock's 70% liquidation preference on Alzheon Common Stock sale creates a potential catalyst if that asset is monetized.
Price Chart
Executive Summary
Aptorum Group (APM) completed its merger with DiamiR Biosciences on July 20, 2026, after domesticating to Delaware and renaming as Niki BioSolutions, Inc. The combined company, now trading under symbol NIKI on Nasdaq, issued 1,979,216 shares to DiamiR stockholders and 814,375 shares plus 179,693 Series A Preferred shares to prior Aptorum holders. The 1-for-10 reverse split was also effected to maintain listing compliance, and a new board was installed with Kira Sheinerman (DiamiR co-founder) as a director holding significant governance rights via a Stockholders Agreement.
Key Facts
- Merger closed on July 20, 2026: Aptorum Group domesticated to Delaware and renamed Niki BioSolutions, Inc. (ticker NIKI).
- DiamiR biosciences became a wholly-owned subsidiary; DiamiR stockholders received 1,979,216 shares of Niki Common Stock.
- 1-for-10 reverse share consolidation was effective July 20, 2026 to maintain Nasdaq minimum bid price.
- New board of directors: Ian Huen (Chairman), Kira Sheinerman, Justin Wu, Douglas Arner, Laura A. Philips; Alidad Mireskandari as Board Observer.
- Stockholders Agreement grants Kira Sheinerman (Primary Stockholder) board designation rights and veto over certain major transactions (Stockholder Reserved Matters) as long as stockholders collectively own ≥25% of outstanding shares.
- Series A Preferred Stock (non-voting, non-convertible) issued to prior Aptorum Class B shareholders, with a 70% liquidation preference on proceeds from any sale of Alzheon Common Stock.
Financial Impact
No revenue, earnings, or cash consideration disclosed for the combined entity. Merger was all-stock; post-merger market cap approximately $6M. Series A preferred stock carries a distribution right to 70% of net cash proceeds from any future sale of Alzheon Common Stock.
Risk Factors
- Concentrated control via Stockholders Agreement may deter potential acquirers or create governance disputes.
- No financial data provided for the combined company — revenue and profitability prospects are unquantified.
- Reverse split and low market cap ($6M) create elevated risk of delisting if bid price falls below $1.00 again.
- Series A Preferred Stock's liquidation preference over Common Stock may reduce equity value for common holders in a sale scenario.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-079416 |
| Document: ea029826201ex10-4.htm | 0001213900-26-079416 |
| Document: ea029826201ex99-2.htm | 0001213900-26-079416 |
| Document: ea029826201ex3-1.htm | 0001213900-26-079416 |
| Document: ea0298262-8k_nikibio.htm | 0001213900-26-079416 |
| Document: ea029826201ex3-3.htm | 0001213900-26-079416 |
| Document: ea029826201ex99-1.htm | 0001213900-26-079416 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 16d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 16d ago | 424B5 | — | awaiting T+1 | — | — |
Jul 20, 2026 14w ago | 8-K | $8.83 $9.54 | ▲ +8.04% | ▲ +7.21% | — |
Jul 16, 2026 14w ago | Press Release | $0.6924 $0.7000 | ▲ +1.10% | ▲ +2.09% | — |
Jun 10, 2026 19w ago | 6-K | $0.9038 $0.8900 | ▼ −1.53% | ▼ −3.23% | — |
Jun 4, 2026 20w ago | EFFECT | $1.09 $1.01 | ▼ −7.34% | ▼ −4.74% | — |
May 14, 2026 23w ago | 6-K | $0.8230 $0.8570 | ▼ −4.13% | ▼ −4.19% | — |
Mar 27, 2026 30w ago | 20-F | $0.8380 $0.7960 | ▲ +5.01% | ▲ +7.90% | — |
Mar 6, 2026 33w ago | Press Release | $0.8000 $0.7930 | ▲ +0.88% | ▲ +0.69% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers